Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Skye Bioscience, Inc. (SKYE) had Weighted-Average Shares Outstanding (Diluted) of 39.66M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-17.62M |
|
-- |
|
-- |
|
$18.24M |
|
$-18.24M |
|
$0.62M |
|
$-17.62M |
|
$-17.71M |
|
$-17.62M |
|
$-17.62M |
|
$-17.62M |
|
$-17.71M |
|
$-18.24M |
|
$-18.06M |
|
39.66M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
39.66M |
$-0.44 |
|
$-0.44 |
|
| Balance Sheet Financials | |
$50.58M |
|
$1.17M |
|
$1.58M |
|
$52.16M |
|
$8.31M |
|
-- |
|
$0.17M |
|
$8.48M |
|
$43.68M |
|
$43.68M |
|
$43.68M |
|
30.99M |
|
| Cash Flow Statement Financials | |
$-19.93M |
|
$-24.66M |
|
$0.02M |
|
$68.42M |
|
$23.84M |
|
$-44.58M |
|
$4.24M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.09 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-19.85M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-40.35% |
|
-40.35% |
|
-33.79% |
|
-40.35% |
|
$1.41 |
|
$-0.50 |
|
$-0.50 |
|